CBER Reorganization Will Proceed Without Siegel; OTRR Director To Retire

CBER Office of Therapeutics Review & Research Director Jay Siegel, MD, is the first high level departure from the agency since the announcement of the reorganization of the Center for Biologics Evaluation & Research

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet